Feb 07, 2025 4:01 pm EST Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Jan 21, 2025 7:30 am EST Atara Biotherapeutics Provides Update on Clinical Programs Related to EBVALLO™ (tabelecleucel) and ATA3219
Jan 16, 2025 8:30 am EST Atara Biotherapeutics Provides Regulatory and Business Update on EBVALLO™ (tabelecleucel)